Roy Maute

June 12, 2023

Dr. Maute is a scientist and biotechnology entrepreneur. Dr. Maute leads Pheast’s Research and Development teams. Prior to Pheast, he led the biomarker and translational science for the clinical anti-CD47 and anti-SIRPA programs at Forty Seven Inc. and Gilead Sciences. Prior to Forty Seven Inc., he co-founded and led the research team at Ab Initio Biotherapeutics, an antibody discovery company which was acquired by Ligand Pharmaceuticals in 2019. Dr. Maute is an author on multiple patents and top tier publications. He was a postdoctoral fellow at Stanford University School of Medicine in the laboratory of Dr. Irving Weissman. Dr. Maute received his Ph.D. in genetics from Columbia University and a B.A. in molecular and cell biology from UC Berkeley.